$36.67
-0.25-0.68%
Last update: 9:30 AM
15 minutes delayed
Revolution Medicines
RVMDNASDAQ
want to know what
the Bulls & Bears Say?
Revolution Medicines (NASDAQ:RVMD) Stock, Analyst Ratings, Price Targets, Forecasts
Revolution Medicines Inc has a consensus price target of $41.63 based on the ratings of 48 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Needham, and Wedbush on May 13, 2024, May 9, 2024, and May 9, 2024, respectively. With an average price target of $45.33 between HC Wainwright & Co., Needham, and Wedbush, there's an implied 23.63% upside for Revolution Medicines Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Needham
Wedbush
Oppenheimer
Raymond James
1calculated from analyst ratings
Analyst Ratings for Revolution Medicines
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | Buy Now | 19.99% | HC Wainwright & Co. | Robert Burns | → $44 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 25.44% | Needham | Ami Fadia | → $46 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 25.44% | Wedbush | Robert Driscoll | $42 → $46 | Maintains | Outperform | Get Alert |
| 04/12/2024 | Buy Now | 22.72% | Oppenheimer | Jay Olson | $43 → $45 | Maintains | Outperform | Get Alert |
| 04/12/2024 | Buy Now | 25.44% | Needham | Ami Fadia | $36 → $46 | Maintains | Buy | Get Alert |
| 04/10/2024 | Buy Now | 30.9% | Raymond James | Laura Prendergast | $36 → $48 | Upgrade | Outperform → Strong Buy | Get Alert |
| 04/08/2024 | Buy Now | -1.83% | Needham | Ami Fadia | $36 → $36 | Maintains | Buy | Get Alert |
| 03/11/2024 | Buy Now | 17.26% | Piper Sandler | Joseph Catanzaro | → $43 | Initiates | → Overweight | Get Alert |
| 03/08/2024 | Buy Now | 19.99% | HC Wainwright & Co. | Robert Burns | $28 → $44 | Maintains | Buy | Get Alert |
| 03/08/2024 | Buy Now | 93.62% | Morgan Stanley | — | $84 → $71 | Maintains | Equal-Weight | Get Alert |
| 02/27/2024 | Buy Now | 14.54% | Wedbush | David Driscoll | $41 → $42 | Maintains | Outperform | Get Alert |
| 01/16/2024 | Buy Now | -1.83% | Raymond James | Laura Prendergast | $30 → $36 | Maintains | Outperform | Get Alert |
| 01/05/2024 | Buy Now | -7.28% | B of A Securities | Alec Stranahan | → $34 | Upgrade | Neutral → Buy | Get Alert |
| 12/20/2023 | Buy Now | 9.08% | UBS | Eliana Merle | → $40 | Initiates | → Buy | Get Alert |
| 11/16/2023 | Buy Now | -18.19% | Raymond James | Dane Leone | → $30 | Initiates | → Outperform | Get Alert |
| 11/13/2023 | Buy Now | -23.64% | HC Wainwright & Co. | Robert Burns | $32 → $28 | Maintains | Buy | Get Alert |
| 11/07/2023 | Buy Now | 6.35% | JP Morgan | Eric Joseph | $47 → $39 | Maintains | Overweight | Get Alert |
| 11/07/2023 | Buy Now | -1.83% | Needham | Ami Fadia | → $36 | Reiterates | Buy → Buy | Get Alert |
| 10/26/2023 | Buy Now | -12.74% | HC Wainwright & Co. | Robert Burns | → $32 | Reiterates | Buy → Buy | Get Alert |
| 10/23/2023 | Buy Now | 17.26% | Oppenheimer | Jay Olson | $40 → $43 | Maintains | Outperform | Get Alert |
| 10/23/2023 | Buy Now | -1.83% | Needham | Ami Fadia | $34 → $36 | Maintains | Buy | Get Alert |
| 10/12/2023 | Buy Now | -7.28% | Needham | Ami Fadia | → $34 | Reiterates | Buy → Buy | Get Alert |
| 09/21/2023 | Buy Now | 28.17% | Stifel | Benjamin Burnett | $37 → $47 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | -7.28% | Needham | Ami Fadia | $35 → $34 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | 9.08% | Oppenheimer | Jay Olson | $35 → $40 | Maintains | Outperform | Get Alert |
| 08/02/2023 | Buy Now | -12.74% | HC Wainwright & Co. | Robert Burns | → $32 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | -4.55% | Needham | Ami Fadia | $31 → $35 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -4.55% | Oppenheimer | Jay Olson | → $35 | Reiterates | → Outperform | Get Alert |
| 05/09/2023 | Buy Now | -12.74% | Needham | Ami Fadia | $34 → $32 | Maintains | Buy | Get Alert |
| 04/12/2023 | Buy Now | -12.74% | HC Wainwright & Co. | Robert Burns | → $32 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | -37.28% | Goldman Sachs | Chris Shibutani | $20 → $23 | Maintains | Neutral | Get Alert |
| 02/28/2023 | Buy Now | 3.63% | Guggenheim | Michael Schmitz | → $38 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -4.55% | Oppenheimer | Jay Olson | $30 → $35 | Maintains | Outperform | Get Alert |
| 02/28/2023 | Buy Now | 3.63% | Needham | Ami Fadia | $32 → $38 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | 3.63% | JP Morgan | Eric Joseph | $32 → $38 | Upgrade | Neutral → Overweight | Get Alert |
| 12/14/2022 | Buy Now | -15.46% | Needham | Ami Fadia | → $31 | Initiates | → Buy | Get Alert |
| 12/08/2022 | Buy Now | -12.74% | HC Wainwright & Co. | Robert Burns | $30 → $32 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | -18.19% | HC Wainwright & Co. | Robert Burns | $37 → $30 | Maintains | Buy | Get Alert |
| 10/21/2022 | Buy Now | -18.19% | Oppenheimer | Jay Olson | → $30 | Initiates | → Outperform | Get Alert |
| 08/17/2022 | Buy Now | 0.9% | HC Wainwright & Co. | Robert Burns | $40 → $37 | Maintains | Buy | Get Alert |
| 08/10/2022 | Buy Now | -18.19% | SVB Leerink | Jonathan Chang | $31 → $30 | Maintains | Outperform | Get Alert |
| 05/20/2022 | Buy Now | -34.55% | B of A Securities | Alec Stranahan | → $24 | Initiates | → Neutral | Get Alert |
| 03/01/2022 | Buy Now | -29.1% | Stifel | Benjamin Burnett | $36 → $26 | Upgrade | Hold → Buy | Get Alert |
| 11/12/2021 | Buy Now | 3.63% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
| 09/23/2021 | Buy Now | -7.28% | Stifel | Benjamin Burnett | — | Initiates | → Hold | Get Alert |
| 08/17/2021 | Buy Now | -15.46% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
| 08/12/2021 | Buy Now | -26.37% | Goldman Sachs | Chris Shibutani | — | Downgrade | Buy → Neutral | Get Alert |
| 08/12/2021 | Buy Now | 3.63% | SVB Leerink | Jonathan Chang | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Revolution Medicines (RVMD) stock?
The latest price target for Revolution Medicines (NASDAQ:RVMD) was reported by HC Wainwright & Co. on May 13, 2024. The analyst firm set a price target for $44.00 expecting RVMD to rise to within 12 months (a possible 19.99% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Revolution Medicines (RVMD)?
The latest analyst rating for Revolution Medicines (NASDAQ:RVMD) was provided by HC Wainwright & Co., and Revolution Medicines reiterated their buy rating.
When was the last upgrade for Revolution Medicines (RVMD)?
The last upgrade for Revolution Medicines Inc happened on April 10, 2024 when Raymond James raised their price target to $48. Raymond James previously had an outperform for Revolution Medicines Inc.
When was the last downgrade for Revolution Medicines (RVMD)?
The last downgrade for Revolution Medicines Inc happened on August 12, 2021 when Goldman Sachs changed their price target from $49 to $27 for Revolution Medicines Inc.
When is the next analyst rating going to be posted or updated for Revolution Medicines (RVMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Revolution Medicines, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Revolution Medicines was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
Is the Analyst Rating Revolution Medicines (RVMD) correct?
While ratings are subjective and will change, the latest Revolution Medicines (RVMD) rating was a reiterated with a price target of $44.00 to $44.00. The current price Revolution Medicines (RVMD) is trading at is $36.67, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.